390 results match your criteria Current Opinion in Drug Discovery & Development [Journal]


Current Treatment Options for Breast Cancer Brain Metastases.

Curr Treat Options Oncol 2019 Feb 15;20(3):19. Epub 2019 Feb 15.

Department of Medicine, Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave, S73, Cleveland, OH, 44195, USA.

Opinion Statement: In the past, the standard of care for treatment of BM was whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), and surgery. There has been a greater role for medical therapies in the last two decades due to the discovery of driver mutations and corresponding targeted therapies. These innovations have dramatically altered the approach to treating these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0618-5DOI Listing
February 2019

Animal models of ischemic stroke and their impact on drug discovery.

Expert Opin Drug Discov 2019 Mar 4;14(3):315-326. Epub 2019 Feb 4.

c Department of Neurology , University Medicine Göttingen , Göttingen , Germany.

Introduction: Representing the leading cause of long-term disability, ischemic stroke urgently needs further research and drug development. This review summarizes current animal models of ischemic stroke that can be used for drug discovery. Areas covered: Several reproducible models of permanent and transient focal cerebral ischemia have been established in a variety of animal species including rats and mice, in which a brain-supplying artery, often the middle cerebral artery, is occluded by mechanical devices including sutures, clips and hooks, pharmacological agents or delivery of blot clots. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17460441.2019.1
Publisher Site
http://dx.doi.org/10.1080/17460441.2019.1573984DOI Listing
March 2019
3 Reads

Anticancer drug discovery using multicellular tumor spheroid models.

Expert Opin Drug Discov 2019 Mar 28;14(3):289-301. Epub 2019 Jan 28.

a Biosciences Laboratory , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS , Meldola , Italy.

Introduction: Despite the increasing financial outlay on cancer research and drug discovery, many advanced cancers remain incurable. One possible strategy for increasing the approval rate of new anticancer drugs for use in clinical practice could be represented by three-dimensional (3D) tumor models on which to perform in vitro drug screening. There is a general consensus among the scientific community that 3D tumor models more closely recapitulate the complexity of tumor tissue architecture and biology than bi-dimensional cell cultures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2019.1570129DOI Listing
March 2019
1 Read

Novel antiviral drug discovery strategies to tackle drug-resistant mutants of influenza virus strains.

Expert Opin Drug Discov 2019 Feb 26;14(2):153-168. Epub 2018 Dec 26.

b Department of Biotechnology , College of Life Science and Biotechnology, Yonsei University , Seoul , South Korea.

Introduction: The emergence of drug-resistant influenza virus strains highlights the need for new antiviral therapeutics to combat future pandemic outbreaks as well as continuing seasonal cycles of influenza. Areas covered: This review summarizes the mechanisms of current FDA-approved anti-influenza drugs and patterns of resistance to those drugs. It also discusses potential novel targets for broad-spectrum antiviral drugs and recent progress in novel drug design to overcome drug resistance in influenza. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2019.1560261DOI Listing
February 2019
2 Reads

Brentuximab vedotin in T-cell lymphoma.

Expert Rev Hematol 2019 Jan 18;12(1):5-19. Epub 2018 Dec 18.

a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Australia.

Introduction: Brentuximab vedotin is an antibody-drug conjugate, which combines a CD30 monoclonal antibody with the microtubule-disrupting agent monomethylauristatin E. The utility of brentuximab vedotin has been explored in a number of diseases, with a recent focus on T-cell lymphoma, particularly systemic anaplastic large-cell lymphoma (sALCL) and cutaneous T-cell lymphoma (CTCL), as well as other peripheral T-cell lymphoma (PTCL) histologies. Areas covered: This review surveys current data on the efficacy of brentuximab vedotin in T-cell lymphoma, as well as embedding it in a therapeutic context by reviewing potential competitor agents in the clinic. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1558399DOI Listing
January 2019
12 Reads

Current state on tryptophan 2,3-dioxygenase inhibitors: a patent review.

Expert Opin Ther Pat 2019 Jan 16;29(1):11-23. Epub 2019 Jan 16.

a Medicinal Chemistry Research Group (CMFA), Louvain Drug Research Institute (LDRI) , Université Catholique de Louvain (UCLouvain) , Brussels , Belgium.

Introduction: Tryptophan-2, 3-dioxygenase (TDO2) is a tryptophan-degrading enzyme constitutively expressed in the liver and to a lesser extend in the brain. Before its link to cancer immunotherapy was discovered in 2011, the search for TDO2 inhibitors was initially driven by depression therapy. In the recent years, TDO2 has drawn an increasing attention as a promising target in both cancer and neuropsychiatric diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543776.2019.1556638DOI Listing
January 2019
1 Read

Current developments in lantibiotic discovery for treating Clostridium difficile infection.

Expert Opin Drug Discov 2019 Jan 27;14(1):71-79. Epub 2018 Nov 27.

a Alderley Park Macclesfield , Evotec , Cheshire , UK.

Introduction: Clostridium difficile is a major cause of healthcare-associated diarrhea linked to the misuse of antimicrobials and the corresponding deleterious impact they have on the protective microbiota of the gut. Resistance to agents used to treat C. difficile including metronizadole and vancomycin has been reported highlighting the need for novel agents. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17460441.2019.1
Publisher Site
http://dx.doi.org/10.1080/17460441.2019.1549032DOI Listing
January 2019
18 Reads

A patent review of the ubiquitin ligase system: 2015-2018.

Expert Opin Ther Pat 2018 Dec 23;28(12):919-937. Epub 2018 Nov 23.

c Barbara Ann Karmanos Cancer Institute, and Departments of Oncology, Pharmacology and Pathology, School of Medicine , Wayne State University , Detroit , MI , USA.

Introduction: Ubiquitin-proteasome system (UPS) has been validated as a novel anticancer drug target in the past 20 years. The UPS contains two distinct steps: ubiquitination of a substrate protein by ubiquitin activating enzyme (E1), ubiquitin conjugating enzyme (E2), and ubiquitin ligase (E3), and substrate degradation by the 26S proteasome complex. The E3 enzyme is the central player in the ubiquitination step and has a wide range of specific substrates in cancer cells, offering great opportunities for discovery and development of selective drugs. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13543776.2018.1
Publisher Site
http://dx.doi.org/10.1080/13543776.2018.1549229DOI Listing
December 2018
25 Reads

Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics.

Expert Opin Emerg Drugs 2018 12 3;23(4):331-347. Epub 2018 Dec 3.

a Rheumatology Department, Royal North Shore Hospital, and, Institute of Bone and Joint Research, Kolling Institute , University of Sydney , Sydney , Australia.

Introduction: Osteoarthritis (OA) is a leading cause of pain and disability among adults with a current prevalence of around 15% and a predicted prevalence of 35% in 2030 for symptomatic OA. It is increasingly recognized as a heterogeneous multi-faceted joint disease with multi-tissue involvement of varying severity. Current therapeutic regimens for OA are only partially effective and often have significant associated toxicities. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14728214.2018.1
Publisher Site
http://dx.doi.org/10.1080/14728214.2018.1547706DOI Listing
December 2018
289 Reads
3.058 Impact Factor

High-throughput drug screens for amyotrophic lateral sclerosis drug discovery.

Expert Opin Drug Discov 2018 Nov 13;13(11):1015-1025. Epub 2018 Oct 13.

a Sheffield Institute for Translational Neuroscience (SITraN) , University of Sheffield , Sheffield , United Kingdom.

Introduction: Amyotrophic lateral sclerosis (ALS) is a rapid adult-onset neurodegenerative disorder characterised by the progressive loss of upper and lower motor neurons. Current treatment options are limited for ALS, with very modest effects on survival. Therefore, there is a unmet need for novel therapeutics to treat ALS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1533953DOI Listing
November 2018
2 Reads

Managing urinary incontinence in women - a review of new and emerging pharmacotherapy.

Expert Opin Pharmacother 2018 Dec 10;19(18):1989-1997. Epub 2018 Oct 10.

a Urology Department, Agostino Gemelli Academic Hospital Foundation IRCCS , Catholic University School of Medicine of Rome , Rome , Italy.

Introduction: The pharmacological treatment of urinary incontinence and overactive bladder (OAB) has been, for a longer time, based on antimuscarinic agents. In recent years, two other pharmacological principles have been introduced for the treatment of OAB and urgency urinary incontinence: the β3-adrenergic agent mirabegron and botulinum neurotoxin. Meanwhile, there is lack of effective drugs for the treatment of stress incontinence. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1532502DOI Listing
December 2018
3 Reads

RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers.

Expert Opin Drug Deliv 2018 Oct 21;15(10):965-982. Epub 2018 Sep 21.

a Department of Pharmaceutical Technology, Faculty of Pharmacy , University of Coimbra , Coimbra , Portugal.

Introduction: Despite the current advances in the discovery of the lung cancer biomarkers and, consequently, in the diagnosis, this pathology continues to be the primary cause of cancer-related death worldwide. In most cases, the illness is diagnosed in an advanced stage, which limits the current treatment options available and reduces the survival rate. Therefore, RNAi-based therapy arises as a promising option to treat lung cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425247.2018.1517744DOI Listing
October 2018
2 Reads

The use of biomarkers as a tool for novel psoriatic disease drug discovery.

Expert Opin Drug Discov 2018 Sep 20;13(9):875-887. Epub 2018 Aug 20.

d Department of Rheumatology , Hammersmith Hospital , London , UK.

Introduction: Psoriatic disease is a relatively new term which encompasses psoriatic arthritis, psoriasis, and associated comorbidities. In this heterogeneous condition, the study of biomarkers is necessary to direct best therapy. Resulting in significant disability and socioeconomic burden, recent recommendations stress the need for tight control in psoriatic disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1508206DOI Listing
September 2018
15 Reads

Developments in lncRNA drug discovery: where are we heading?

Expert Opin Drug Discov 2018 Sep 6;13(9):837-849. Epub 2018 Aug 6.

a Center for Therapeutic Innovation and Department of Psychiatry and Behavioral Sciences , University of Miami Miller School of Medicine , Miami , FL , USA.

Introduction: The central dogma of molecular biology, which states that the only role of long RNA transcripts is to convey information from gene to protein, was brought into question in recent years due to discovery of the extensive presence and complex roles of long noncoding RNAs (lncRNAs). Furthermore, lncRNAs were found to be involved in pathogenesis of multiple diseases and thus represent a new class of therapeutic targets. Translational efforts in the lncRNA field have been augmented by progress in optimizing the chemistry and delivery platforms of lncRNA-targeting modalities, including oligonucleotide-based drugs and CRISPR-Cas9. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1501024DOI Listing
September 2018
2 Reads

Structure-kinetic relationships that control the residence time of drug-target complexes: insights from molecular structure and dynamics.

Curr Opin Chem Biol 2018 06 6;44:101-109. Epub 2018 Jul 6.

Department of Chemistry, Institute for Chemical Biology & Drug Discovery, Stony Brook University, Stony Brook, New York, USA; Department of Radiology, Stony Brook University School of Medicine, Stony Brook, New York, USA.

Time-dependent target occupancy is a function of both the thermodynamics and kinetics of drug-target interactions. However, while the optimization of thermodynamic affinity through approaches such as structure-based drug design is now relatively straight forward, less is understood about the molecular interactions that control the kinetics of drug complex formation and breakdown since this depends on both the ground and transition state energies on the binding reaction coordinate. In this opinion we highlight several recent examples that shed light on current approaches that are elucidating the factors that control the life-time of the drug-target complex. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cbpa.2018.06.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066427PMC
June 2018
3 Reads

Proteomic approaches for novel systemic lupus erythematosus (SLE) drug discovery.

Authors:
Yaxi Li Tianfu Wu

Expert Opin Drug Discov 2018 Aug 4;13(8):765-777. Epub 2018 Jun 4.

a Department of Biomedical Engineering , University of Houston , Houston , TX , USA.

Introduction: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a high risk of morbidity and mortality; however, there is no cure and the current medications are far from optimal in addressing efficacy and safety concerns. Over the past decade, various emerging technologies have been used in the search for novel drug targets of SLE which have resulted in numerous promising data. However, the systematic review and careful digestion of this information have been lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1480718DOI Listing
August 2018
2 Reads

Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.

Curr Treat Options Oncol 2018 May 28;19(7):37. Epub 2018 May 28.

Oncology Department, Centre Hospitalier Universitaire Vaudois, BH09/725, Rue du Bugnon 46, 1000, Lausanne, Switzerland.

Opinion Statement: A decade after the discovery of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (EML4-ALK) rearrangements in non-small cell lung cancer (NSCLC), several inhibitors have gained regulatory approval, and their sequential use has deferred platinum-based chemotherapy to later lines of therapy. Nevertheless, although most ALK-driven tumors dramatically respond to ALK TKIs , all patients ultimately develop drug-resistant disease. Analysis of post-progression biopsy samples has provided invaluable insight into the mechanisms of resistance, now informing on subsequent therapeutic strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0553-xDOI Listing
May 2018
2 Reads

Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.

Diabetes Obes Metab 2018 10 19;20(10):2467-2471. Epub 2018 Jun 19.

Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, Toronto, Canada.

This study (registered with PROSPERO, CRD42018085967) compares the efficacy (i.e. pro-cognitive effects) and acceptability of antidiabetic agents for Alzheimer's disease (AD) and mild cognitive impairment (MCI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dom.13373DOI Listing
October 2018
6 Reads
1 Citation
6.360 Impact Factor

Mitochondrial disease patient motivations and barriers to participate in clinical trials.

PLoS One 2018 17;13(5):e0197513. Epub 2018 May 17.

Mitochondrial Medicine Frontier Program, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.

Background: Clinical treatment trials are increasingly being designed in primary mitochondrial disease (PMD), a phenotypically and genetically heterogeneous collection of inherited multi- system energy deficiency disorders that lack effective therapy. We sought to identify motivating factors and barriers to clinical trial participation in PMD.

Methods: A survey study was conducted in two independent mitochondrial disease subject cohorts. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197513PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957366PMC
December 2018
3 Reads

A systems biology approach to antimalarial drug discovery.

Expert Opin Drug Discov 2018 07 8;13(7):617-626. Epub 2018 May 8.

c Laboratório de Malária , Instituto René Rachou, Fundação Oswaldo Cruz , Belo Horizonte , Brazil.

Introduction: In spite of significant efforts to reduce malaria deaths, this disease still kills around 445,000 people every year. Overcoming drug resistance is one of the main goals of current malaria research programs. This is challenging, since the biology of Plasmodium is not fully understood, requiring the development of advanced models for data analysis in the search for new antimalarials. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17460441.2018.1
Publisher Site
http://dx.doi.org/10.1080/17460441.2018.1471056DOI Listing
July 2018
7 Reads

Emerging therapeutic targets for treatment of leishmaniasis.

Expert Opin Ther Targets 2018 06 9;22(6):467-486. Epub 2018 May 9.

a Department of Medicine , Institute of Medical Sciences, Banaras Hindu University , Varanasi , UP , India.

Introduction: Parasitic diseases that pose a threat to human life include leishmaniasis - caused by protozoan parasite Leishmania species. Existing drugs have limitations due to deleterious side effects like teratogenicity, high cost and drug resistance. This calls for the need to have an insight into therapeutic aspects of disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728222.2018.1472241DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047532PMC
June 2018
5 Reads

Discovery and development of varenicline for smoking cessation.

Expert Opin Drug Discov 2018 07 28;13(7):671-683. Epub 2018 Mar 28.

a Molecular Targets and Medications Discovery Branch, Intramural Research Program , National Institute on Drug Abuse, National Institutes of Health , Baltimore , MD , USA.

Introduction: Tobacco use causes one premature death every six seconds. Current smoking cessation aids include nicotine replacement therapies, bupropion, and varenicline. Although more than 70% of smokers express a desire to quit, fewer than 3% remain abstinent for more than one year, highlighting a critical need for more efficacious smoking cessation treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1458090DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179352PMC
July 2018
19 Reads

Recent developments with tau-based drug discovery.

Expert Opin Drug Discov 2018 05 1;13(5):399-410. Epub 2018 Mar 1.

a Department of Neurochemistry, Inge Grundke-Iqbal Research Floor , New York State Institute for Basic Research in Developmental Disabilities , Staten Island , NY , USA.

Introduction: Alzheimer's disease (AD), which accounts for three fourth of all cases of dementia, is a major public health problem in modern society and, yet, there is no effective treatment available that can prevent or inhibit this chronic progressive neurodegenerative disease. A major current drug target is intraneuronal abnormally hyperphosphorylated microtubule-associated protein tau which is a histopathological hallmark of this disease and of a family of neurodegenerative diseases called tauopathies. Areas covered: In this review, the authors discuss a growing number of studies that describe the nature and mechanism of tau pathology and various drug discovery options and most recent developments in tau-based therapeutics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1445084DOI Listing
May 2018
11 Reads

Evaluation of cAMS for C microtracer ADME studies: opportunities to change the current drug development paradigm.

Bioanalysis 2018 Mar 16;10(5):321-339. Epub 2018 Feb 16.

Novartis Pharma AG, Novartis Institutes for Biomedical Research, PK Sciences, Fabrikstrasse 14, CH-4002 Basel, Switzerland.

Aim: Although regulatory guidances require human metabolism information of drug candidates early in the development process, the human mass balance study (or hADME study), is performed relatively late. hADME studies typically involve the administration of a C-radiolabelled drug where biological samples are measured by conventional scintillation counting analysis. Another approach is the administration of therapeutic doses containing a C-microtracer followed by accelerator mass spectrometry (AMS) analysis, enabling hADME studies completion much earlier. Read More

View Article

Download full-text PDF

Source
https://www.future-science.com/doi/10.4155/bio-2017-0216
Publisher Site
http://dx.doi.org/10.4155/bio-2017-0216DOI Listing
March 2018
21 Reads

Optogenetics in cancer drug discovery.

Expert Opin Drug Discov 2018 05 15;13(5):459-472. Epub 2018 Feb 15.

a Department of Biochemistry and Molecular Biology , Medical University of Lublin , Lublin , Poland.

Introduction: The discovery and domestication of biomolecules that respond to light has taken a light of its own, providing new molecular tools with incredible spatio-temporal resolution to manipulate cellular behavior. Areas covered: The authors herein analyze the current optogenetic tools in light of their current, and potential, uses in cancer drug discovery, biosafety and cancer biology. Expert opinion: The pipeline from drug discovery to the clinic is plagued with drawbacks, where most drugs fail in either efficacy or safety. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1437138DOI Listing
May 2018
10 Reads

Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014-2017).

Expert Opin Ther Pat 2018 Apr 13;28(4):299-316. Epub 2018 Feb 13.

a Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences , Shandong University , Ji'nan , PR China.

Introduction: To deal with the rapid emergence of drug resistance challenges, together with the difficulty to eradicate the virus, off-target effects and significant cumulative drug toxicities, it is still imperative to develop next-generation anti-HIV agents with novel chemical classes or new mechanisms of action. Areas covered: We primarily focused on current strategies to discover novel anti-HIV agents. Moreover, examples of anti-HIV lead compounds were mainly selected from recently patented publications (reported between 2014 and 2017). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543776.2018.1438410DOI Listing
April 2018
5 Reads

Pharmacovigilance: pharmacists' perspective on spontaneous adverse drug reaction reporting.

Integr Pharm Res Pract 2017 22;6:91-98. Epub 2017 Mar 22.

Faculty of Pharmacy, Umm-Al-Qura University, Makkah, Saudi Arabia.

Globally, adverse drug reactions (ADRs), one of the leading causes of morbidity and mortality, will continue to pose a threat to public health as long as drugs are being used to treat various ailments. Prompt ADR reporting is crucial in ensuring drug safety. The aim of this narrative review was to highlight the role of pharmacists in pharmacovigilance and to identify barriers and facilitators toward ADR reporting documented in the literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IPRP.S105881DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774327PMC
March 2017
2 Reads

An update on the advancing high-throughput screening techniques for patch clamp-based ion channel screens: implications for drug discovery.

Expert Opin Drug Discov 2018 03 17;13(3):269-277. Epub 2018 Jan 17.

a Nanion Technologies GmbH , Munich , Germany.

Introduction: Automated patch clamp (APC) devices have become commonplace in many industrial and academic labs. Their ease-of-use and flexibility have ensured that users can perform routine screening experiments and complex kinetic experiments on the same device without the need for months of training and experience. APC devices are being developed to increase throughput and flexibility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1428555DOI Listing
March 2018
14 Reads
3.470 Impact Factor

The latest animal models of ovarian cancer for novel drug discovery.

Expert Opin Drug Discov 2018 03 17;13(3):249-257. Epub 2018 Jan 17.

a Department of Cancer Immunology and Virology , Dana-Farber Cancer Institute , Boston , MA , USA.

Introduction: Epithelial ovarian cancer is a heterogeneous disease classified into five subtypes, each with a different molecular profile. Most cases of ovarian cancer are diagnosed after metastasis of the primary tumor and are resistant to traditional platinum-based chemotherapeutics. Mouse models of ovarian cancer have been utilized to discern ovarian cancer tumorigenesis and the tumor's response to therapeutics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1426567DOI Listing
March 2018
6 Reads

Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery.

Expert Opin Drug Deliv 2018 04 22;15(4):369-378. Epub 2018 Jan 22.

f Perrigo Company Minneapolis , Product Development , Minneapolis , MN , USA.

Introduction: The blood brain barrier is a functional barrier allowing the entry into the brain of only essential nutrients, excluding other molecules. Its structure, although essential to keep the harmful entities out, is also a major roadblock for pharmacological treatment of brain diseases. Several alternative invasive drug delivery approaches, such as transcranial drug delivery and disruption of blood brain barrier have been explored, with limited success and several challenges. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425247.2018.1429401DOI Listing
April 2018
7 Reads

Parents' attitude, awareness and behaviour towards influenza vaccination in Pakistan.

Hum Vaccin Immunother 2018 04 25;14(4):952-957. Epub 2018 Jan 25.

f School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor Darul Ehsan , Malaysia.

National immunization program of Pakistan does not include Influenza vaccines. The low rate of immunization might be attributed to the poor knowledge of influenza vaccination in Pakistan. Current study was aimed to assess the knowledge and attitude of influenza vaccination among parents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21645515.2017.1415686DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893193PMC
April 2018
8 Reads
2.131 Impact Factor

Lost in translation? A critical look at the role that animal models of obsessive compulsive disorder play in current drug discovery strategies.

Expert Opin Drug Discov 2018 03 23;13(3):211-220. Epub 2017 Dec 23.

a Centro de Investigación en Reproducción Animal , CINVESTAV-Universidad Autónoma de Tlaxcala , Tlaxcala , México.

Introduction: Obsessive-compulsive disorder (OCD) is a severe neuropsychiatric illness estimated to affect between 1-3% of the population. In today's literature, there are a number well-validated and convincing animal models of OCD described. Areas covered: Herein, the authors look at the role that animal models of OCD (including transgenic models, deer mouse stereotypy, quinpirole sensitization, post-training signal attenuation, and mouse marble burying) have played in determining the current directions of OCD drug discovery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1417379DOI Listing
March 2018
14 Reads

Particle morphology: an important factor affecting drug delivery by nanocarriers into solid tumors.

Expert Opin Drug Deliv 2018 04 27;15(4):379-395. Epub 2017 Dec 27.

a Department of Pharmaceutics , China Pharmaceutical University , Nanjing , PR China.

Introduction: Efficient delivery of drugs by nanoparticles deep into solid tumors is the precondition of valid cancer therapy. Despite profound understanding of the delivery of spherical nanoparticles into solid tumor attained, insufficient attention was paid to anisotropic particles. Actually, owing to their structural asymmetry, some non-spherical particles exhibit significant advantages over their spherical counterparts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425247.2018.1420051DOI Listing
April 2018
8 Reads

Urinary peptidomics in kidney disease and drug research.

Expert Opin Drug Discov 2018 03 19;13(3):259-268. Epub 2017 Dec 19.

b Mosaiques Diagnostics GmbH , Hannover , Germany.

Introduction: Due to its close connection with the renal system, urine is considered a valuable source of information in kidney disease research. Peptidomics methods focus on the discovery of endogenous peptides, given their wide range of biological functions and diagnostic and therapeutic potential. Representing a non-invasive and sensitive method, technological prospects of urinary peptidomics should be evaluated in the context of drug discovery and research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1418320DOI Listing
March 2018
7 Reads

Phenotypic screening approaches for Chagas disease drug discovery.

Expert Opin Drug Discov 2018 02 20;13(2):141-153. Epub 2017 Dec 20.

a Drugs for Neglected Diseases initiative (DNDi), R&D Department , Geneva , Switzerland.

Introduction: Chagas disease, caused by the parasite Trypanosoma cruzi, is a global public health issue. Current treatments targeting the parasite are limited to two old nitroheterocyclic drugs with serious side effects. The need for new and safer drugs has prompted numerous drug discovery efforts to identify compounds suitable for parasitological cure in the last decade. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1417380DOI Listing
February 2018
6 Reads

Improving the attrition rate of Lanthipeptide discovery for commercial applications.

Expert Opin Drug Discov 2018 02 1;13(2):155-167. Epub 2017 Dec 1.

a Department of Biological Sciences , Texas A&M University, College Station , College Station , TX , USA.

Introduction: Lanthipeptides are a class of ribosomally synthesized and post-translationally modified peptides. Lanthipeptides with antimicrobial activity are referred to as lantibiotics. Lantibiotics are generally active against Gram-positive bacteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1410137DOI Listing
February 2018
14 Reads

Novel avenues for drug discovery in diabetic kidney disease.

Expert Opin Drug Discov 2018 01 16;13(1):65-74. Epub 2017 Nov 16.

b Division of Nephrology, Department of Internal Medicine , University of Michigan , Ann Arbor , MI , USA.

Introduction: Diabetic kidney disease (DKD) has emerged as major cause of morbidity and mortality. After progressing to renal failure, over 70% of DKD patients are dead with five years. New treatments to slow this progression are desperately needed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1398731DOI Listing
January 2018
8 Reads

Measuring what matters to rare disease patients - reflections on the work by the IRDiRC taskforce on patient-centered outcome measures.

Orphanet J Rare Dis 2017 11 2;12(1):171. Epub 2017 Nov 2.

Modus Outcomes, Letchworth Garden City, UK.

Our ability to evaluate outcomes which genuinely reflect patients' unmet needs, hopes and concerns is of pivotal importance. However, much current clinical research and practice falls short of this objective by selecting outcome measures which do not capture patient value to the fullest. In this Opinion, we discuss Patient-Centered Outcomes Measures (PCOMs), which have the potential to systematically incorporate patient perspectives to measure those outcomes that matter most to patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13023-017-0718-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667521PMC
November 2017
8 Reads

The application of molecular topology for ulcerative colitis drug discovery.

Expert Opin Drug Discov 2018 01 1;13(1):89-101. Epub 2017 Nov 1.

a Medicinal Chemistry/Laboratory of Bioactive Research and Development, Department of Biological Sciences, Faculty of Exact Sciences , University of La Plata (UNLP) , La Plata , Buenos Aires , Argentina.

Introduction: Although the therapeutic arsenal against ulcerative colitis has greatly expanded (including the revolutionary advent of biologics), there remain patients who are refractory to current medications while the safety of the available therapeutics could also be improved. Molecular topology provides a theoretic framework for the discovery of new therapeutic agents in a very efficient manner, and its applications in the field of ulcerative colitis have slowly begun to flourish. Areas covered: After discussing the basics of molecular topology, the authors review QSAR models focusing on validated targets for the treatment of ulcerative colitis, entirely or partially based on topological descriptors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1396314DOI Listing
January 2018
5 Reads

Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis.

Expert Opin Ther Targets 2017 12;21(12):1095-1110

a Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Department of Molecular Medicine , University of Pavia , Pavia , Italy.

Introduction: Systemic amyloidosis occurs when one of a growing list of circulating proteins acquires an abnormal fold, aggregates and gives rise to extracellular amyloid deposits in different body sites, leading to organ dysfunction and eventually death. Current approaches are mainly aimed at lowering the supply of the amyloidogenic precursor or at stabilizing it in a non-amyloidogenic state, thus interfering with the initial phases of amyloid formation and toxicity. Areas covered: Improved understanding of the pathophysiology is indicating novel steps and molecules that could be therapeutically targeted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728222.2017.1398235DOI Listing
December 2017
6 Reads

Fatty acid synthase (FASN) as a therapeutic target in breast cancer.

Expert Opin Ther Targets 2017 11 21;21(11):1001-1016. Epub 2017 Sep 21.

c Department of Medicine and Experimental Pathology , Mayo Clinic , Rochester , MN , USA.

Introduction: Ten years ago, we put forward the metabolo-oncogenic nature of fatty acid synthase (FASN) in breast cancer. Since the conception of this hypothesis, which provided a model to explain how FASN is intertwined with various signaling networks to cell-autonomously regulate breast cancer initiation and progression, FASN has received considerable attention as a therapeutic target. However, despite the ever-growing evidence demonstrating the involvement of FASN as part of the cancer-associated metabolic reprogramming, translation of the basic science-discovery aspects of FASN blockade to the clinical arena remains a challenge. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14728222.2017.1
Publisher Site
http://dx.doi.org/10.1080/14728222.2017.1381087DOI Listing
November 2017
45 Reads

Cross-Cultural Analysis of Medicinal Plants commonly used in Ethnoveterinary Practices at South Waziristan Agency and Bajaur Agency, Federally Administrated Tribal Areas (FATA), Pakistan.

J Ethnopharmacol 2018 Jan 14;210:443-468. Epub 2017 Sep 14.

Department of Zoology, Kohat University of Science and Technology, Kohat 26000, Pakistan. Electronic address:

Ethnopharmacological Relevance: In remote areas, medicinal plants have an imperative role in curing various livestock's ailments. In Pakistan, people residing in remote areas including South Waziristan Agency and Bajaur Agency depend on traditional herbal remedies for treating their domestic animals. Medicinal plants are an important part of the medical system in these Agencies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jep.2017.09.007DOI Listing
January 2018
27 Reads

Type II transmembrane serine proteases as potential target for anti-influenza drug discovery.

Expert Opin Drug Discov 2017 11 5;12(11):1139-1152. Epub 2017 Sep 5.

b Department of Biotechnology, College of Life Science and Biotechnology , Yonsei University , Seoul , South Korea.

Introduction: The outbreak of an influenza pandemic as well as the continued circulation of seasonal influenza highlights the need for effective antiviral therapies. The emergence of drug-resistant strains further necessitates the development of novel antivirals that target the host factors crucial for viral replication. Area covered: This review summarizes the current understanding of the structural and functional properties of type II transmembrane serine proteases (TTSPs) as a proteolytic activator of influenza virus infection and discusses their potential as antiviral targets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2017.1372417DOI Listing
November 2017
41 Reads

Ophthalmic Start-Up Chief Executive Officers' Perceptions of Development Hurdles.

Ophthalmic Res 2018 26;59(2):110-114. Epub 2017 Aug 26.

PRN PharmaFarm, LLC, Cheyenne, WY, USA.

Purpose: To identify current challenges facing ophthalmic pharmaceutical start-ups in developing new products.

Methods: Surveys were distributed to the chief executive officer (CEO) or president of ophthalmic start-ups.

Results: The survey attracted 24 responses from 78 surveys distributed (31%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000479376DOI Listing
March 2018
5 Reads

An update on drug design strategies to prevent acquired sensorineural hearing loss.

Authors:
Daniel Bodmer

Expert Opin Drug Discov 2017 11 30;12(11):1161-1167. Epub 2017 Aug 30.

a Department of Biomedicine, Head and Neck Surgery , University of Basel Hospital , Basel , Switzerland.

Introduction: Acute sensorineural hearing loss is a dramatic event for the patient. Different pathologies might result in acute sensorineural hearing loss, such as sudden hearing loss, exposure to medications/drugs or loud sound. Current therapeutic approaches include steroids and hyperbaric oxygen in addition to other methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2017.1372744DOI Listing
November 2017
26 Reads

The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.

Expert Opin Drug Discov 2017 11 23;12(11):1169-1178. Epub 2017 Aug 23.

b Atkinson Morley Regional Neuroscience Centre , St George's University Hospitals NHS Foundation Trust , London , UK.

Introduction: Brivaracetam (BRV) is a new AED currently licensed for the adjunctive treatment of adult patients with focal epilepsies. It is a ligand of the ubiquitous synaptic vesicle glycoprotein 2A (SV2A). Areas covered: This paper covers the preclinical and subsequent clinical development of BRV focusing on the discovery of the SV2A protein as the main target for levetiracetam (LEV) and the main similarities and differences between LEV and BRV in terms of pharmacodynamic and pharmacokinetic properties. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2017.1366985DOI Listing
November 2017
38 Reads

Reaction phenotyping to assess victim drug-drug interaction risks.

Authors:
Li Di

Expert Opin Drug Discov 2017 11 18;12(11):1105-1115. Epub 2017 Aug 18.

a Pharmacokinetics, Dynamics and Metabolism , Pfizer Inc , Groton , CT , USA.

Introduction: Reaction phenotyping provides critical information regarding the fraction metabolized (f) of drug candidates. It has become increasingly important in drug discovery and development as it can be used to assess victim drug-drug interaction potential, guide structural modification to reduce f, inform clinical study design, predict individual variability in pharmacokinetics, and evaluate the impact of genetic polymorphisms. Areas covered: The currently available in vitro and in vivo methods for reaction phenotyping are summarized along with their advantages, limitations and timings for application during the different stages of drug discovery and development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2017.1367280DOI Listing
November 2017
31 Reads

Small molecules as therapy for uveitis: a selected perspective of new and developing agents.

Expert Opin Pharmacother 2017 Sep 7;18(13):1311-1323. Epub 2017 Aug 7.

b Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health , Institute of Clinical Pharmacology and Toxicology , Berlin , Germany.

Introduction: Intraocular inflammation (uveitis) remains a significant burden of legal blindness. Because of its immune mediated and chronic recurrent nature, common therapy includes corticosteroids, disease-modifying anti-rheumatic drugs and more recently biologics as immune modulatory agents. The purpose of this article is to identify the role of new treatment approaches focusing on small molecules as therapeutic option in uveitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2017.1361408DOI Listing
September 2017
12 Reads

Harm reduction in the USA: the research perspective and an archive to David Purchase.

Harm Reduct J 2017 07 26;14(1):51. Epub 2017 Jul 26.

The Baron Edmond de Rothschild Chemical Dependency Institute, Icahn School of Medicine at Mount Sinai, 39 Broadway Suite 530, New York, NY, 10006, USA.

The history of harm reduction in the USA has led to the development of some of the most important methods for treating persons for drug use disorders, such as methadone and buprenorphine for opiate use disorder. However, there has been fierce political resistance to implementation and scale-up of harm reduction in the USA. This resistance is rooted in historical demonization of particular psychoactive drugs that were associated with stigmatized racial/ethnic groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12954-017-0178-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530540PMC
July 2017
31 Reads

Drug Delivery Innovations to Address Global Health Challenges for Pediatric and Geriatric Populations (Through Improvements in Patient Compliance).

Authors:
Joshua Boateng

J Pharm Sci 2017 11 20;106(11):3188-3198. Epub 2017 Jul 20.

Department of Pharmaceutical, Chemical and Environmental Sciences, Faculty of Engineering and Science, University of Greenwich, Medway, Central Avenue, Chatham Maritime, Kent ME4 4TB, UK. Electronic address:

Despite significant advances in pharmaceutical and biotechnological drug discovery, the global population is plagued with many challenging diseases. These are further compounded by anticipated explosion in an ageing population, which presents several problems such as polypharmacy, dysphagia, and neurologic conditions, resulting in noncompliance and disease complications. For antibiotics, poor compliance, can result in development of drug-resistant infections which can be fatal. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00223549173050
Publisher Site
http://dx.doi.org/10.1016/j.xphs.2017.07.009DOI Listing
November 2017
4 Reads